A brief note on the scope of RNA interference(RNAi) therapy in mitigating COVID-19

Together with the use of number repurposed/ repositioned antiviral drugs and immunomodulatory agents against severe acute respiratory coronavirus 2 (SARS-CoV-2) infection, currently several vaccines are under human trials to mitigate COVID-19 worldwide. Although appear be effective in maximum cases or trials; however, associated side effects, required induction long-lasting immunity, finally, safety concerns significance terms their consistent application/ administration. A vast research on SARS-CoV-2 genomics its similarities SARS-CoV-1 Middle East Respiratory Syndrome (MERS-CoV) have unraveled viral avoidance host immunity which creates a challenge course vaccine development although being used commercially Such an unsteady circumstance led scientists also think new remedial approach i.e., RNA interference (RNAi) therapy inhibit proliferation by degrading RNAs. Present review discussed such strategy effectiveness during ongoing pandemic.